Location Directory

Clinical trials in Detroit, Michigan

This page shows live ClinicalTrials.gov search results for Detroit, Michigan, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7248

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions: Paradise Ultrasound Renal Denervation Treatment; Device
Lead sponsor: ReCor Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 46
States / cities: Long Beach, California • Los Angeles, California • Sacramento, California + 39 more

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: DS-3939a; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: Sarasota, Florida • Locust Grove, Georgia • Westwood, Kansas + 9 more

Conditions: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions: Saruparib, Placebo, Enzalutamide, Darolutamide, Abiraterone; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 42
States / cities: Hot Springs, Arkansas • Springdale, Arkansas • Beverly Hills, California + 36 more

Conditions: Muscle Invasive Bladder Cancer
Interventions: Durvalumab, Cisplatin, Gemcitabine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,063 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Hidradenitis Suppurativa
Interventions: Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 36
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • North Little Rock, Arkansas + 32 more

Conditions: Advanced Solid Cancers
Interventions: BNT329, CA19-9-targeting monoclonal antibody; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 4
States / cities: Denver, Colorado • Orlando, Florida • Detroit, Michigan + 1 more

Conditions: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Interventions: Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 799 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 50
States / cities: Fresno, California • Irvine, California • Los Alamitos, California + 43 more

Conditions: Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
Interventions: Tonlamarsen, Placebo; Drug
Lead sponsor: Kardigan, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 13
States / cities: Arvada, Colorado • Homestead, Florida • Port Orange, Florida + 10 more

Conditions: Prostate Cancer
Interventions: AAA817, ARPI, Standard of Care; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 42
States / cities: Homewood, Alabama • Tucson, Arizona • Orange, California + 37 more

Conditions: Hepatitis
Interventions: Larsucosterol, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 92
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more

Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
Interventions: Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel, Mosunetuzumab, Patient Observation, Polatuzumab Vedotin, Positron Emission Tomography, Tisagenlecleucel; Biological · Procedure · Drug + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 95
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more

Conditions: Type 1 Diabetes (T1D)
Interventions: Set of implementation strategies; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 1 Year and older
Enrollment: 9,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Alexander City, Alabama • Orlando, Florida • Birmingham, Michigan + 5 more

Clinical trials in Detroit, Michigan

Filter and sort this location

Live official records

Global Paradise System US Post Approval Study

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Universal Type 1 Diabetes Screening in Pediatrics